Citigroup Cuts Boston Scientific (NYSE:BSX) Price Target to $48.00

Boston Scientific (NYSE:BSX) had its target price reduced by Citigroup from $50.00 to $48.00 in a report released on Monday morning,Benzinga reports. They currently have a neutral rating on the medical equipment provider’s stock.

Several other research firms have also recently commented on BSX. Stifel Nicolaus set a $60.00 target price on Boston Scientific in a research note on Wednesday, July 29th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $60.00 price target on shares of Boston Scientific in a research report on Thursday, July 30th. Argus reiterated a “hold” rating on shares of Boston Scientific in a research note on Friday, July 31st. Sanford C. Bernstein reissued an “outperform” rating and set a $54.00 price objective on shares of Boston Scientific in a research report on Saturday. Finally, BTIG Research cut their target price on shares of Boston Scientific from $60.00 to $56.00 and set a “buy” rating on the stock in a research note on Wednesday, September 9th. Twenty-two investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $66.31.

Boston Scientific Price Performance

Boston Scientific stock opened at $41.55 on Monday. The firm has a market cap of $60.21 billion, a PE ratio of 16.82, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58. Boston Scientific has a 52-week low of $41.50 and a 52-week high of $105.65. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. The company’s 50 day moving average is $46.72 and its two-hundred day moving average is $50.90.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating the consensus estimate of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The company had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. During the same quarter last year, the company posted $0.75 EPS. The firm’s revenue was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, research analysts expect that Boston Scientific will post 3.25 EPS for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney acquired 186,240 shares of the company’s stock in a transaction dated Monday, August 3rd. The shares were acquired at an average price of $48.33 per share, for a total transaction of $9,000,979.20. Following the acquisition, the chief executive officer owned 1,590,024 shares in the company, valued at $76,845,859.92. The trade was a 13.27% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director David C. Habiger bought 2,100 shares of the business’s stock in a transaction dated Wednesday, August 5th. The shares were acquired at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the transaction, the director directly owned 17,160 shares in the company, valued at approximately $816,644.40. This represents a 13.94% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired a total of 194,522 shares of company stock worth $9,385,210 over the last ninety days. Corporate insiders own 0.34% of the company’s stock.

Hedge Funds Weigh In On Boston Scientific

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BSX. South Plains Financial Inc. purchased a new stake in shares of Boston Scientific during the 4th quarter worth approximately $39,000. Clal Insurance Enterprises Holdings Ltd acquired a new position in shares of Boston Scientific in the 1st quarter valued at $28,000. Cassaday & Co Wealth Management LLC purchased a new position in shares of Boston Scientific in the 1st quarter valued at $32,000. Measured Wealth Private Client Group LLC raised its stake in Boston Scientific by 244.9% during the 1st quarter. Measured Wealth Private Client Group LLC now owns 545 shares of the medical equipment provider’s stock worth $34,000 after acquiring an additional 387 shares in the last quarter. Finally, Hilton Head Capital Partners LLC acquired a new stake in Boston Scientific during the 4th quarter worth $54,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Company Profile

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company’s portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.